Olio Labs Analysis: $5M Raised
What is Olio Labs?
Olio Labs builds the Combination Design Engine for designing drug combinations. The company says its platform identifies combination therapies with better outcomes and fewer side effects. Its public materials highlight GLP-1 and obesity drug research, including sex-difference findings from a March 2025 study.
Revenue
$8.4M
Product Features & Capabilities
- Combination therapeutics, AI-driven development, targeting complex protein interactions, designed for effectiveness, reduced side effects.
How much Olio Labs raised
Pre-Seed - $4.5 Million
August 1, 2023Lead Investor: ZAKA VC, Y Combinator, Unpopular Ventures, Pioneer Fund
Who are the founders of Olio Labs
DT
David Tingley
Founder
TR
Tom Roseberry
Founder
Market Focus
Olio Labs primarily focuses on the biotechnology industry, specifically in the development of combination therapeutics using artificial intelligence to target protein interactions for more effective medical treatments.
Investors
- Pioneer Fund
- SciFounders
- Scrum Ventures
- Y Combinator
- ZAKA VC
- Unpopular Ventures
Competitors Overview
Olio Labs operates in the biotechnology sector, focusing on developing advanced combination therapeutics using artificial intelligence. Its main competitors include:
-
Owkin: This AI biotech company integrates human and artificial intelligence to identify new treatments and accelerate clinical trials. Owkin emphasizes multimodal patient data, which may provide a broader data perspective compared to Olio Labs' focus on protein interactions.
-
Zephyr AI: Specializes in personalized healthcare solutions by leveraging healthcare and biological data. Its patient-centric approach may offer a distinct advantage in tailoring treatments compared to Olio Labs' broader therapeutic focus.
-
AMPLY Discovery: Uses AI and next-generation sequencing to accelerate drug discovery. AMPLY's emphasis on digitizing life's diversity for medicine discovery may provide a unique angle in the drug development process.
-
Iambic: Focuses on AI-driven drug discovery, utilizing physics-based algorithms to optimize medicines. This approach may differ from Olio Labs' combination therapeutics strategy.
-
Nabla Bio: Specializes in antibody design with a focus on manufacturability, safety, and efficacy. This specific focus on antibody development may set it apart from Olio Labs' broader therapeutic targets.
-
Nimbus Therapeutics: Specializes in targeted therapeutics for cancer and other diseases, having raised significant funding.
-
Schrodinger: Provides a web-based simulation and modeling tool for drug discovery, with a strong financial backing.
-
Evozyne: Focuses on protein development and has secured substantial funding, which may enhance its capabilities in the market.
Each of these competitors has unique methodologies and focuses that may provide advantages in specific areas of drug discovery and development compared to Olio Labs.
Business Model
Utilizes AI for drug development; revenue from partnerships and licensing agreements.
See something that needs updating? Suggest edits to this profile.